A Randomized Doubled Blind Phase Ii Study Exploring The Safety And Efficacy Of Nintedanib (Bibf1120) As Second Line Therapy For Patients (Pts) With Differentiated Thyroid Carcinoma (Dtc) Progressing After First Line Therapy: Eortc 1209.
JOURNAL OF CLINICAL ONCOLOGY（2018）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要